Article Authors: Marcus Hompesch, Aleksandra Hawryluk, Moises Hernandez, Beena Uchil, Alyssa Wilmington, Lucas Peterson
Abstract
To show pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence between Myxredlin, a novel, ready-to-use regular human insulin 1 U/mL formulation (BAX-HI), and Novolin R 100 U/mL concentrate diluted to 1 U/mL (NOVO-HI).